Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Greasley

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Endocrinology and Metabolism|August 25, 2020
Identification of Proteins Associated with the Early Restoration of Insulin Sensitivity After Biliopancreatic DiversionCecilia Karlsson, Kristina Wallenius, Anna Walentinsson, et al.
Canadian Journal of Physiology and Pharmacology|June 30, 2026
Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin systemAnthony P Davenport, Majid Anwar, Rhoda E Kuc, et al.
BMJ Open|February 2, 2022
Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort studyJesse K Fitzpatrick, Jingrong Yang, Andrew P Ambrosy, et al.
British Journal of Pharmacology|August 19, 2024
The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trialHongtao Yu, Peter J Greasley, Hiddo J Lambers Heerspink, et al.
Diabetes, Obesity & Metabolism|March 3, 2020
A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetesSkander Mulder, Ann Hammarstedt, Sunil B Nagaraj, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 9, 2020
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical TrialK Melissa Hallow, David W Boulton, Robert C Penland, et al.
Pulmonary Pharmacology & Therapeutics|May 2, 2021
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19Marie Fisk, Magnus Althage, Sven Moosmang, et al.
Pharmacology Research & Perspectives|August 4, 2015
Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approachSarah K Walsh, Claire Y Hepburn, Oliver Keown, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 25, 2016
Effect of Tenapanor on Interdialytic Weight Gain in Patients on HemodialysisGeoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 27, 2023
The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentanVandana Veenit, Hiddo J L Heerspink, Christine Ahlström, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Endocrinology and Metabolism|August 25, 2020
Identification of Proteins Associated with the Early Restoration of Insulin Sensitivity After Biliopancreatic DiversionCecilia Karlsson, Kristina Wallenius, Anna Walentinsson, et al.
Canadian Journal of Physiology and Pharmacology|June 30, 2026
Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin systemAnthony P Davenport, Majid Anwar, Rhoda E Kuc, et al.
BMJ Open|February 2, 2022
Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort studyJesse K Fitzpatrick, Jingrong Yang, Andrew P Ambrosy, et al.
British Journal of Pharmacology|August 19, 2024
The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trialHongtao Yu, Peter J Greasley, Hiddo J Lambers Heerspink, et al.
Diabetes, Obesity & Metabolism|March 3, 2020
A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetesSkander Mulder, Ann Hammarstedt, Sunil B Nagaraj, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 9, 2020
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical TrialK Melissa Hallow, David W Boulton, Robert C Penland, et al.
Pulmonary Pharmacology & Therapeutics|May 2, 2021
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19Marie Fisk, Magnus Althage, Sven Moosmang, et al.
Pharmacology Research & Perspectives|August 4, 2015
Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approachSarah K Walsh, Claire Y Hepburn, Oliver Keown, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 25, 2016
Effect of Tenapanor on Interdialytic Weight Gain in Patients on HemodialysisGeoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 27, 2023
The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentanVandana Veenit, Hiddo J L Heerspink, Christine Ahlström, et al.
Pageof 9